On April 15, 2025, MetaVia Inc. (MTVA) announced positive results from the 4-week Phase 1 multiple ascending dose (MAD) trial of DA-1726 for the treatment of obesity. The results showed a mean weight loss of 4.3% at Day 26 in the 32 mg dose with only mild gastrointestinal (GI) adverse events reported in 4/6 subjects, most of which resolved within 24 hours. In addition, a mean reduction in waist circumference of 1.6 inches was demonstrated along with a mean lowering of -5.3 mg/dL in fasting blood glucose. The company is planning to initiate Part 3 of the Phase 1 trial in Wegovy early drop-out patients in an effort to show superiority with respect to tolerability and safety. Part 3 of the Phase 1 trial should initiate in the 4Q25.
